Rekovar, a leading innovator in neonatal health technology, is excited to announce the successful completion of its feasibility readiness phase for its state-of-the-art wireless withdrawal detection and monitoring system designed to tackle neonatal abstinence syndrome (NAS). This significant milestone marks a pivotal moment in the company's mission to revolutionize the care of newborns suffering from NAS, a condition resulting from opioid exposure.

The completion of the feasibility readiness phase underscores Rekovar's commitment to developing reliable, efficient, and groundbreaking healthcare solutions. This achievement indicates that the proposed system is not only technically viable but also poised to meet the urgent needs of the healthcare industry, particularly in the neonatal intensive care unit (NICU) setting where the care for NAS-affected newborns is critic

Rekovar has successfully ran three adult clinical trials with the collaboration with Vital Signs Research Group, a hypoxia lab solely dedicated to running hypoxia studies throughout October to December 2023. The goal of the study was to validate Rekovar’s NeoMonki Wearable’s (Rekovar’s next-generation health monitoring wearable) pulse oximeter for precision accuracy.

Rekovar is thrilled to announce that our multicenter central Institutional Review Board (IRB) approval for the next-generation Neonatal Abstinence Syndrome (NAS) monitoring system has been officially approved by the WIRB Connexus Group (WCG). This pivotal approval paves the way for expanded clinical trials and research efforts aimed at enhancing the care and treatment of newborns affected by NAS.

As we turn the page on another chapter in our journey, we are thrilled to announce that Rekovar has moved to a new office! This move is not just a change of location; it's a significant leap toward realizing our vision for the future, embodying our growth, and reinforcing our commitment to our team, clients, and community.

We are pleased to announce that on February 2023, our research project received approval from WIRB-Copernicus Group (WCG) for our multicenter clinical trial central IRB. This milestone is a testament to our commitment to ethical research practices and our project's potential impact. With this approval, we are poised to move forward with our study, adhering to the highest standards of research integrity and participant safety. This achievement brings us one step closer to realizing our research goals and making a meaningful difference for NAS-affected babies.

In an extraordinary leap forward for neonatal health technology, Rekovar is thrilled to announce our recent attainment of Phase II Small Business Innovation Research (SBIR) funding from the National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services' National Institutes of Health (NIH). This pivotal funding, now totaling an impressive $2.5 million after a 106% increase from the initial $1,215,174 award, is set to propel the development and commercialization of our groundbreaking wireless withdrawal detection and monitoring system for neonatal abstinence syndrome (NAS).

Exciting news from our research department! We have officially started our pilot study on NAS babies in collaboration with Children's Hospital Orange County (CHOC). This study is critical for collecting data and advancing our efforts to develop our first-generation NAS monitoring system.

In a significant advancement for neonatal care, Rekovar, a up and coming medical device startup, has been awarded a grant from the National Institute on Drug Abuse (NIDA) to develop a wireless withdrawal detection and monitoring system aimed at combating neonatal abstinence syndrome (NAS). The grant, part of the broader HEAL Initiative to address the opioid crisis, underscores the critical need for innovative solutions in the fight against opioid addiction and its effects on the youngest members of society.